vs
Side-by-side financial comparison of Neuphoria Therapeutics Inc. (NEUP) and SuperCom Ltd (SPCB). Click either name above to swap in a different company.
Neuphoria Therapeutics Inc. is the larger business by last-quarter revenue ($15.0M vs $14.2M, roughly 1.1× SuperCom Ltd). Neuphoria Therapeutics Inc. runs the higher net margin — 75.1% vs 37.5%, a 37.6% gap on every dollar of revenue.
Neuphoria Therapeutics Inc is a clinical-stage biopharmaceutical company focused on researching and developing innovative targeted therapies for unmet medical needs in neurological and psychiatric conditions, including anxiety, treatment-resistant depression, and other central nervous system disorders. Its core R&D efforts prioritize delivering safer, more effective treatment options for patient groups with limited existing care alternatives.
Super.com is a technology company headquartered in San Francisco and co-founded by Hussein Fazal and Henry Shi. The company provides financial services, including reward programs and travel bookings.
NEUP vs SPCB — Head-to-Head
Income Statement — Q3 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.0M | $14.2M |
| Net Profit | $11.3M | $5.3M |
| Gross Margin | — | 61.2% |
| Operating Margin | 79.8% | 16.3% |
| Net Margin | 75.1% | 37.5% |
| Revenue YoY | — | -1.5% |
| Net Profit YoY | — | 79.5% |
| EPS (diluted) | $6.55 | $1.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | — | $14.2M | ||
| Q1 25 | $15.0M | — | ||
| Q2 24 | — | $14.4M | ||
| Q2 23 | — | $14.1M | ||
| Q2 22 | — | $6.3M |
| Q2 25 | — | $5.3M | ||
| Q1 25 | $11.3M | — | ||
| Q2 24 | — | $3.0M | ||
| Q2 23 | — | $-2.6M | ||
| Q2 22 | — | $-5.2M |
| Q2 25 | — | 61.2% | ||
| Q1 25 | — | — | ||
| Q2 24 | — | 52.3% | ||
| Q2 23 | — | 27.2% | ||
| Q2 22 | — | 41.8% |
| Q2 25 | — | 16.3% | ||
| Q1 25 | 79.8% | — | ||
| Q2 24 | — | 7.7% | ||
| Q2 23 | — | -12.2% | ||
| Q2 22 | — | -49.9% |
| Q2 25 | — | 37.5% | ||
| Q1 25 | 75.1% | — | ||
| Q2 24 | — | 20.6% | ||
| Q2 23 | — | -18.3% | ||
| Q2 22 | — | -82.4% |
| Q2 25 | — | $1.32 | ||
| Q1 25 | $6.55 | — | ||
| Q2 24 | — | $1.19 | ||
| Q2 23 | — | $-10.66 | ||
| Q2 22 | — | $-1.54 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $17.0M | $15.0M |
| Total DebtLower is stronger | — | $23.6M |
| Stockholders' EquityBook value | $26.0M | $37.3M |
| Total Assets | $30.7M | $65.5M |
| Debt / EquityLower = less leverage | — | 0.63× |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | — | $15.0M | ||
| Q1 25 | $17.0M | — | ||
| Q2 24 | — | $5.7M | ||
| Q2 23 | — | $1.1M | ||
| Q2 22 | — | $2.9M |
| Q2 25 | — | $23.6M | ||
| Q1 25 | — | — | ||
| Q2 24 | — | $29.2M | ||
| Q2 23 | — | $32.9M | ||
| Q2 22 | — | $32.3M |
| Q2 25 | — | $37.3M | ||
| Q1 25 | $26.0M | — | ||
| Q2 24 | — | $13.8M | ||
| Q2 23 | — | $3.5M | ||
| Q2 22 | — | $3.7M |
| Q2 25 | — | $65.5M | ||
| Q1 25 | $30.7M | — | ||
| Q2 24 | — | $49.6M | ||
| Q2 23 | — | $40.8M | ||
| Q2 22 | — | $42.7M |
| Q2 25 | — | 0.63× | ||
| Q1 25 | — | — | ||
| Q2 24 | — | 2.11× | ||
| Q2 23 | — | 9.49× | ||
| Q2 22 | — | 8.68× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $11.5M | $-2.2M |
| Free Cash FlowOCF − Capex | — | $-3.6M |
| FCF MarginFCF / Revenue | — | -25.3% |
| Capex IntensityCapex / Revenue | — | 10.0% |
| Cash ConversionOCF / Net Profit | 1.02× | -0.41× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-14.0M |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | — | $-2.2M | ||
| Q1 25 | $11.5M | — | ||
| Q2 24 | — | $-950.0K | ||
| Q2 23 | — | $-3.4M | ||
| Q2 22 | — | $-4.1M |
| Q2 25 | — | $-3.6M | ||
| Q1 25 | — | — | ||
| Q2 24 | — | $-1.6M | ||
| Q2 23 | — | $-4.5M | ||
| Q2 22 | — | $-4.4M |
| Q2 25 | — | -25.3% | ||
| Q1 25 | — | — | ||
| Q2 24 | — | -10.8% | ||
| Q2 23 | — | -31.5% | ||
| Q2 22 | — | -70.4% |
| Q2 25 | — | 10.0% | ||
| Q1 25 | — | — | ||
| Q2 24 | — | 4.2% | ||
| Q2 23 | — | 7.4% | ||
| Q2 22 | — | 4.4% |
| Q2 25 | — | -0.41× | ||
| Q1 25 | 1.02× | — | ||
| Q2 24 | — | -0.32× | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
